TipRanks
Advertisement
Advertisement
SCYNEXIS: Buy Rating Reaffirmed with $32 Price Target Unchanged Amid Strong Cash Position and Promising Pipeline
PremiumRatingsSCYNEXIS: Buy Rating Reaffirmed with $32 Price Target Unchanged Amid Strong Cash Position and Promising Pipeline
1M ago
Scynexis reports Q2 EPS 63c, consensus (51c)
Premium
The Fly
Scynexis reports Q2 EPS 63c, consensus (51c)
2M ago
GSK closer to relaunching Brexafemme, says Brookline
Premium
The Fly
GSK closer to relaunching Brexafemme, says Brookline
2M ago
Scynexis trading halted, news pending
PremiumThe FlyScynexis trading halted, news pending
4M ago
SCYNEXIS Stockholders Approve One-for-Eight Reverse Split
Premium
Company Announcements
SCYNEXIS Stockholders Approve One-for-Eight Reverse Split
4M ago
Scynexis announces 1-for-8 reverse stock split
Premium
The Fly
Scynexis announces 1-for-8 reverse stock split
4M ago
Scynexis: Strategic Pivot to Rare Disease With ADPKD Asset, Strengthened Balance Sheet, and Antifungal Optionality Support Buy Rating and $4 Target
PremiumRatingsScynexis: Strategic Pivot to Rare Disease With ADPKD Asset, Strengthened Balance Sheet, and Antifungal Optionality Support Buy Rating and $4 Target
5M ago
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease
Premium
Company Announcements
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease
6M ago
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline
Premium
Company Announcements
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline
6M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―